The Cancer Prevention Steering Committee (CPSC) addresses the design, prioritization, and evaluation of phase 2 and phase 3 clinical trial concepts in the fields of cancer prevention, screening and surveillance across a broad range of cancer and precancerous conditions in diverse patient populations that are seen within the NCI Community Oncology Research Program (NCORP). Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The CPSC's membership comprises representatives from the NCORP Research Bases, R01 investigators, community oncologists, biostatisticians, patient advocates, and NCI Staff.
Co-Chairs
Julie Bauman, M.D., M.P.H.
George Washington University
Jason A. Zell, D.O., M.P.H.
University of California Irvine
Members
Banu K. Arun, M.D.
University of Texas M.D. Anderson Cancer Center
Stephanie Blank, M.D.
Icahn School of Medicine at Mount Sinai
Carolyn Y. Fang, Ph.D.
Fox Chase Cancer Center
Leslie Ford, M.D.
National Cancer Institute, DCP
Allison Grimes, M.D., M.S.C.I.
University of Texas Health Science Center at San Antonio
Leila Hamroun
Patient Advocate
Brandy Heckman-Stoddard, Ph.D., M.P.H.
National Cancer Institute, DCP
Yan Ji, M.D., Ph.D.
Metro Minnesota Community Oncology Research Consortium
John M. Kirkwood, M.D.
University of Pittsburgh
Sandra Lee, Sc.D.
Dana-Farber Cancer Institute, Harvard University
Philip J. Lupo, Ph.D., M.P.H.
Emory University
Patrick Nana-Sinkam, M.D.
Virginia Commonwealth University
Lauren Elizabeth Nye, M.D.
University of Kansas Cancer Center
Philip C. Prorok, Ph.D.
National Cancer Institute, DCP
Sharon Rivera-Sanchez
Patient Advocate
Wendy Rubinstein, M.D., Ph.D.
National Cancer Institute, DCP
Marie E. Wood, M.D.
University of Colorado
NCI CCCT Program Director
Mehrdad Mohseni, M.D.
mehrdad.mohseni@nih.gov